In summary, our data provides pre-clinical evidence for a translationally feasible pharmacological approach, oral delivery of riluzole, to augment BDNF in vivo to mitigate cancer chemotherapy-induced adverse impact on neurogenesis, microglial activation, and cognitive function. This evidence concerns the gene BDNF and cancer.